Allergic reactions to COVID-19 vaccines are rare, according to new researchTrusted Source published in JAMA Network Open.
This large, prospective study involved the Pfizer-BioNTech COVID-19 vaccine, one of three COVID-19 vaccines currently in use in the United States.
“We assume that these lessons will be generalizable to the Moderna and other mRNA vaccines with similar excipients and constructs,” Dr. Elizabeth J. Phillips, a professor in the department of medicine at Vanderbilt University Medical Center in Tennessee, said in an editorialTrusted Source that accompanied the study.
About The Study
The researchers gathered data from December 27, 2020 to February 22, 2021 at Sheba Medical Center in Israel.
More than 8,000 people with allergies went through risk assessment using an algorithm that included a detailed questionnaire.
Slightly more than 400 participants were defined as “highly allergic.” Of those, 71 percent were women.
This group received the vaccine under medical supervision. Following the first dose:
Almost 98 percent of participants had no allergic reaction.
Slightly more than 1 percent of participants developed a mild allergic response, such as skin eruptions, flushing, swelling of the tongue or uvula, or cough.
Less than 1 percent of participants had an anaphylactic reaction, a potentially life-threatening condition.